Crossmark

La empagliflozina reduce la mortalidad cardiovascular en pacientes diabéticos con eventos cardiovasculares previos

Crossref DOI link: https://doi.org/10.1016/j.semerg.2015.10.010

Published Print: 2016-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Seguí Díaz, M.
License Information

Text and Data Mining valid from 2016-07-01
More Information

This article is maintained by: Elsevier

Article Title: La empagliflozina reduce la mortalidad cardiovascular en pacientes diabéticos con eventos cardiovasculares previos

Journal Title: SEMERGEN - Medicina de Familia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.semerg.2015.10.010

Content Type: simple-article

Copyright: © 2015 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. All rights reserved.